Compare Stocks: RGNX, BHVN, ADMA, and NBTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.26 +3.9%	$8.55	$7.21 ▼ $20.46	$2.07B	0.74	2.49 million shs	3.78 million shs
BHVN Biohaven	$13.62 -0.9%	$13.80	$7.48 ▼ $18.57	$2.07B	1.26	2.00 million shs	1.43 million shs
NBTX Nanobiotix	$39.67 +0.4%	$37.74	$6.90 ▼ $57.14	$2.00B	0.78	122,670 shs	87,887 shs
RGNX REGENXBIO	$10.50 +1.9%	$9.86	$5.45 ▼ $16.19	$532.48M	0.94	1.89 million shs	1.52 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.93%	+6.31%	+1.09%	+9.33%	-51.16%
BHVN Biohaven	-0.79%	+1.55%	-15.12%	+40.15%	-10.46%
NBTX Nanobiotix	+0.38%	+4.81%	-3.48%	-6.90%	+472.85%
RGNX REGENXBIO	+1.94%	+9.15%	-29.20%	+0.77%	+26.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$9.26 +3.9%	$8.55	$7.21 ▼ $20.46	$2.07B	0.74	2.49 million shs	3.78 million shs
BHVN Biohaven	$13.62 -0.9%	$13.80	$7.48 ▼ $18.57	$2.07B	1.26	2.00 million shs	1.43 million shs
NBTX Nanobiotix	$39.67 +0.4%	$37.74	$6.90 ▼ $57.14	$2.00B	0.78	122,670 shs	87,887 shs
RGNX REGENXBIO	$10.50 +1.9%	$9.86	$5.45 ▼ $16.19	$532.48M	0.94	1.89 million shs	1.52 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	+3.93%	+6.31%	+1.09%	+9.33%	-51.16%
BHVN Biohaven	-0.79%	+1.55%	-15.12%	+40.15%	-10.46%
NBTX Nanobiotix	+0.38%	+4.81%	-3.48%	-6.90%	+472.85%
RGNX REGENXBIO	+1.94%	+9.15%	-29.20%	+0.77%	+26.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	2.50	Moderate Buy	$18.67	101.58% Upside
BHVN Biohaven	2.67	Moderate Buy	$21.63	58.73% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$37.33	-5.89% Downside
RGNX REGENXBIO	2.62	Moderate Buy	$23.82	126.84% Upside

Current Analyst Ratings Breakdown

Latest RGNX, BHVN, ADMA, and NBTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	NBTX Nanobiotix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	ADMA ADMA Biologics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$20.00 ➝ $17.00
7/14/2026	RGNX REGENXBIO	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	ADMA ADMA Biologics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/1/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
6/29/2026	BHVN Biohaven	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$11.00
6/29/2026	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$12.00 ➝ $11.00
6/26/2026	BHVN Biohaven	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/24/2026	RGNX REGENXBIO	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
6/22/2026	RGNX REGENXBIO	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$17.00 ➝ $18.00
6/22/2026	RGNX REGENXBIO	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$27.00 ➝ $32.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$510.17M	4.21	$0.68 per share	13.62	$2.01 per share	4.61
BHVN Biohaven	N/A	N/A	N/A	N/A	$0.39 per share	N/A
NBTX Nanobiotix	$36.87M	54.46	N/A	N/A	($1.97) per share	-20.14
RGNX REGENXBIO	$170.44M	3.18	N/A	N/A	$2.03 per share	5.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$146.93M	$0.68	13.62	9.35	N/A	32.43%	39.98%	28.08%	N/A
BHVN Biohaven	-$738.82M	-$5.67	N/A	N/A	N/A	N/A	-866.46%	-137.99%	8/10/2026 (Estimated)
NBTX Nanobiotix	-$27.11M	N/A	N/A	396.70	N/A	N/A	N/A	N/A	9/29/2026 (Estimated)
RGNX REGENXBIO	-$193.88M	-$5.60	N/A	N/A	N/A	-330.23%	-232.50%	-61.02%	8/6/2026 (Estimated)

Latest RGNX, BHVN, ADMA, and NBTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	BHVN Biohaven	-$0.7610	N/A	N/A	N/A	$0.49 million	N/A
8/6/2026	Q2 2026	RGNX REGENXBIO	$0.0787	N/A	N/A	N/A	$97.63 million	N/A
8/5/2026	Q2 2026	ADMA ADMA Biologics	$0.1633	$0.16	-$0.0033	$0.16	$125.34 million	$124.40 million
5/14/2026	Q1 2026	RGNX REGENXBIO	-$1.36	-$1.72	-$0.36	-$1.72	$25.84 million	$6.39 million
5/6/2026	Q1 2026	ADMA ADMA Biologics	$0.1933	$0.19	-$0.0033	$0.19	$139.98 million	$114.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.51	6.95	3.93
BHVN Biohaven	1.87	7.41	7.41
NBTX Nanobiotix	N/A	1.09	1.09
RGNX REGENXBIO	N/A	2.62	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
BHVN Biohaven	88.78%
NBTX Nanobiotix	38.81%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.90%
BHVN Biohaven	13.80%
NBTX Nanobiotix	3.45%
RGNX REGENXBIO	14.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	231.77 million	222.73 million	Optionable
BHVN Biohaven	239	150.56 million	129.78 million	Optionable
NBTX Nanobiotix	100	50.62 million	48.87 million	Not Optionable
RGNX REGENXBIO	370	51.70 million	44.35 million	Optionable

RGNX, BHVN, ADMA, and NBTX Headlines

Recent News About These Companies

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 4 at 2:28 AM | americanbankingnews.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of "Moderate Buy" from Analysts

August 4 at 2:28 AM | marketbeat.com

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

August 3 at 7:05 AM | prnewswire.com

REGENXBIO (RGNX) Projected to Post Earnings on Thursday

July 30, 2026 | marketbeat.com

New Strong Sell Stocks for July 23rd

July 23, 2026 | zacks.com

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

July 21, 2026 | prnewswire.com

Regenxbio prices expected $100M public offering

July 20, 2026 | thepharmaletter.comT

REGENXBIO (NASDAQ:RGNX) Shares Up 8% - Should You Buy?

July 20, 2026 | marketbeat.com

RegenXBio Raises Capital Through Public Equity Offering

July 20, 2026 | tipranks.com

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

July 18, 2026 | prnewswire.com

REGENXBIO (NASDAQ:RGNX) Shares Gap Down - Here's What Happened

July 17, 2026 | marketbeat.com

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

July 17, 2026 | prnewswire.com

RGNX stock slumps 15% after-hours — what’s driving the selloff?

July 17, 2026 | msn.com

REGENXBIO files prospectus for up to $100M common stock offering

July 16, 2026 | msn.com

REGENXBIO Announces Proposed Public Offering of Common Stock

July 16, 2026 | prnewswire.com

REGENXBIO (NASDAQ:RGNX) Downgraded to "Strong Sell" Rating by Zacks Research

July 16, 2026 | marketbeat.com

Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm

July 13, 2026 | globenewswire.com

REGENXBIO (NASDAQ:RGNX) Stock Price Down 6.8% - Time to Sell?

July 10, 2026 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 10, 2026 | marketbeat.com

Y Intercept Hong Kong Ltd Invests $2.31 Million in REGENXBIO Inc. $RGNX

July 9, 2026 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Insider Sells 2,161 Shares

July 7, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, BHVN, ADMA, and NBTX Company Descriptions

ADMA Biologics NASDAQ:ADMA

$9.26 +0.35 (+3.93%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$9.10 -0.15 (-1.67%)

As of 04:34 AM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Biohaven NYSE:BHVN

$13.62 -0.13 (-0.92%)

Closing price 08/5/2026 03:59 PM Eastern

Extended Trading

$13.62 -0.01 (-0.07%)

As of 04:32 AM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Nanobiotix NASDAQ:NBTX

$39.67 +0.15 (+0.38%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$39.21 -0.46 (-1.17%)

As of 04:15 AM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

REGENXBIO NASDAQ:RGNX

$10.50 +0.20 (+1.94%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$10.68 +0.18 (+1.69%)

As of 04:11 AM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGNX, BHVN, ADMA, and NBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGNX, BHVN, ADMA, and NBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGNX, BHVN, ADMA, and NBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, BHVN, ADMA, and NBTX Company Descriptions

ADMA Biologics NASDAQ:ADMA

Biohaven NYSE:BHVN

Nanobiotix NASDAQ:NBTX

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGNX, BHVN, ADMA, and NBTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGNX, BHVN, ADMA, and NBTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGNX, BHVN, ADMA, and NBTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX, BHVN, ADMA, and NBTX Company Descriptions

ADMA Biologics NASDAQ:ADMA

Biohaven NYSE:BHVN

Nanobiotix NASDAQ:NBTX

REGENXBIO NASDAQ:RGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools